Abstract:Purpose: The successful development of controlled release formulations for proteins requires that the protein not be denatured during the manufacturing process. The major objective was to develop formulations that stabilize two recombinant human proteins, human growth hormone (rhGH) and interferon-gamma (rhIFN-gamma), at high protein concentrations (> 100 mg/mL) in organic solvents commonly used for microencapsulation, methylene chloride and ethyl acetate. Methods: Several excipients were screened to obtain the maximum solubility of each protein. These formulations (aqueous, lyophilized, milled, spray dried, or isoelectric precipitate) were then rapidly screened by emulsification in the organic solvent followed by recovery into excess buffer. Additional screening was performed with solid protein that was suspended in the organic solvent and then recovered with excess buffer. The recovery of native protein was determined by native size exclusion chromatography (SEC-HPLC) and circular dichroism (CD). The selected formulations were encapsulated in polylactic-coglycolic acid (PLGA) microspheres by either water-in-oil-in-water (W/O/W) or solid-in-oil-in-water (S/O/W) methods. The initial protein released from the microspheres incubated at physiological conditions was analyzed by SEC-HPLC, CD, and biological assays. Results: The stability of a given formulation in the rapid screening method correlated well with stability during encapsulation in PLGA microspheres. Formulations of rhGH containing Tween 20 or 80 resulted in lower recovery of native protein, while trehalose and mannitol formulations (phosphate buffer, pH 8.0) yielded complete recovery of native rhGH. Other additives such as carboxymethyl cellulose, gelatin, and dextran 70 were not effective stabilizers, and polyethylene glycol provided some stabilization of rhGH. Trehalose/rhGH (1:4 mass ratio) and mannitol/rhGH (1:2 mass ratio) formulations (potassium phosphate buffer, pH 8.0) were lyophilized, reconstituted to 200 and 400 mg/mL rhGH, respectively, and then encapsulated in PLGA microspheres. The protein was released from these microspheres in its native state. Lyophilized formulations of rhGH yielded analogous results indicating the ability of trehalose and mannitol to stabilize the protein. Small solid particles of rhGH generated by spray drying (both air and freeze-drying) formulations containing Tween 20 or PEG were stable in ethyl acetate, but not methylene chloride. Similar results were also obtained with rhIFN-gamma (137 mg/mL in succinate buffer, pH 5.0), where both mannitol and trehalose were observed to stabilize the protein during exposure to the organic solvents resulting in the release of native rhIFN-gamma from PLGA microspheres. Conclusions: The rapid screening method allowed the development of stable concentrated protein solutions or solid protein formulations that could be successfully encapsulated in PLGA microspheres. The excipients observed to stabilize these proteins function by preferential hydration of the protein, and in the dry state (e.g., trehalose) may stabilize the protein via water substitution yielding a protective coating around the protein surface. Studies of other proteins should provide further insight into this mechanism of protein stabilization during encapsulation.

Evaluation on the Conditions Influencing the Chemical Stability of Recombinant Human Granulocyte Colony Stimulating Factor

New RP-HPLC Method for Precise Determination of Chemical Stability of Rhg-Csf Products

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor

Influence of Reducing Agents on Biosafety and Biocompatibility of Gold Nanoparticles

Determination of Critical Influencing Factor on Ph Stability of Yuxingcao Injection

Optimization of lyoprotectant for recombinant human acidic fibroblast growth factor by response surface methodology

Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study

Preclinical Safety Evaluation of Oral Drug of Human Granulocyte-Macrophage Colony-Stimulating Factor Expressed in Silkworm Pupae As Bioreactor

Expression and the physical and chemical characterizations studies of recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein with long-acting bio-function

The optimiztion of high cell-density culture of G-CSF us recombinamt Escherichia coli

Effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor (Cys17Ser) in aqueous two-phase systems containing chelated metal ions

Investigation of the pH-dependent aggregation mechanisms of GCSF using low resolution protein characterization techniques and advanced molecular dynamics simulations

Identification and Characterization of Forced Degradation Products and Stability-indicating Assay for Notoginsenoside Fc by Using UHPLC-Q-TOF-MS and UHPLC-MS/MS: Insights into Stability Profile and Degradation Pathways.

Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing

Exploring the effects of whey protein components on the interaction and stability of cyanidin-3-O-glucoside

Purification and characterization of recombinant human superoxide dismutase integrated with resilin-like polypeptide

Effect of Rutin on the Physicochemical and Gel Characteristics of Myofibrillar Protein under Oxidative Stress

A Novel Process for One-Step Separation and Cyclodextrin Inclusion of Ginsenoside Rg5 from Ginseng Stem-Leaf Saponins (GSLS): Preparation, Characterization, and Evaluation of Storage Stability and Bioactivity

[Treatment of Chemotherapy-Induced Neutropenia Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor: a Multi-Center Randomized Controlled Phase II Clinical Study].

Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres